<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798954</url>
  </required_header>
  <id_info>
    <org_study_id>SKT</org_study_id>
    <nct_id>NCT00798954</nct_id>
  </id_info>
  <brief_title>Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial</brief_title>
  <acronym>SINGLEKISS</acronym>
  <official_title>A Multi-center Trial to Evaluate Paclitaxel- and Sirolimus-eluting Stents in Provisional T-stenting With Kissing Balloon Technique in the Treatment of Bifurcation Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vulnerable Plaque Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vulnerable Plaque Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of DES have not diminished the need of improved treatment strategies , especially the&#xD;
      treatment of bifurcation lesions still leave much to be clarified. Particularly, for&#xD;
      bifurcation lesions where stenting the main branch could result in an obstruction of a vital&#xD;
      side branch, many reports have been about using 2 drug-eluting stents. Resulting in less than&#xD;
      favorable, target lesion revascularization (TLR) rates, with 10-15% for main branch and&#xD;
      11-40% for side branch.&#xD;
&#xD;
      In Japan, the PERFECT multi-center registry evaluated outcomes of single stenting plus&#xD;
      kissing balloon technique after Directional Coronary Atherectomy (DCA) removal of tissue&#xD;
      plaques. TLR rates for both main branch and side branch were a satisfactory 1.3%. However,&#xD;
      the DCA technique is mainly suitable for proximal coronary artery lesions, and takes skilled&#xD;
      operators.&#xD;
&#xD;
      For the treatment of relatively distal bifurcation lesions, where first POBA is performed,&#xD;
      then the lesion is stented, followed by kissing balloon technique to fully expand the side&#xD;
      branch, is considered a viable treatment. The Toyohashi Heart Center outcomes from August&#xD;
      2004 for this single stent and kissing ballooning technique, using the sirolimus-eluting&#xD;
      stent on bifurcation lesions, achieved a satisfactory 5.2% TLR for both main and side&#xD;
      branches, suggesting that using two stents may not be necessarily the ideal treatment.&#xD;
&#xD;
      The paclitaxel-eluting stent is expected to become available in Japan from June 2007. This&#xD;
      stent's cells can be expanded to a maximum of 3.5mm, which should provide a larger lumen&#xD;
      access for side-branch treatment.&#xD;
&#xD;
      As such, we developed this study to compare the outcomes of paclitaxel-eluting and&#xD;
      sirolimus-eluting stents in bifurcation lesions that require side branch dilatation using the&#xD;
      kissing ballooning technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Primary Endpoints Target lesion revascularization after one year&#xD;
&#xD;
        2. Secondary Endpoints Secondary endpoints be evaluated in terms of safety and efficacy.&#xD;
&#xD;
      2-1 Safety&#xD;
&#xD;
        1. Major complications associated with procedure (death, QMI, CABG)&#xD;
&#xD;
        2. Major complications at follow-up (within 9 months) (death, QMI, CABG)&#xD;
&#xD;
        3. Target vessel revascularization (TVR) performed within 9 months 2-2 Efficacy&#xD;
&#xD;
      1. Acute angiographic success&#xD;
&#xD;
        -  Minimum lumen diameter (MLD)&#xD;
&#xD;
           ・% stenosis 2. Angiographic success at follow-up&#xD;
&#xD;
        -  Minimum lumen diameter (MLD)&#xD;
&#xD;
           ・% stenosis&#xD;
&#xD;
        -  Loss index&#xD;
&#xD;
        -  Late loss&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>TAXUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cypher</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting coronary stent (Cypher)</intervention_name>
    <description>Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.</description>
    <arm_group_label>Cypher</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting stent (TAXUS)</intervention_name>
    <description>Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.</description>
    <arm_group_label>TAXUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 to &lt;81 years and are able to undergo CABG&#xD;
&#xD;
          2. Females who are not pregnant&#xD;
&#xD;
          3. Patients who present with angina symptoms or myocardial ischemia&#xD;
&#xD;
          4. Patients available for post-procedural observation and coronary angiography at 9&#xD;
             months&#xD;
&#xD;
          5. Patients who have signed patient informed consent&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Bifurcation lesion with ≥2.0mm side branch diameter as confirmed angiographically (the&#xD;
             Duke Classification (see Reference 1)&#xD;
&#xD;
          2. The target lesion without remote lesions in the same vessel.&#xD;
&#xD;
          3. De novo lesion or non-stented restenosed lesion&#xD;
&#xD;
          4. Lesion which is eligible for stent implantation&#xD;
&#xD;
          5. Main branch reference vessel diameter of ≥2.5 mm by visual assessment&#xD;
&#xD;
          6. If two or more bifurcated lesions are present in the reference lesion, the proximal&#xD;
             lesion shall be included in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient Exclusion Criteria:&#xD;
&#xD;
          1. Patients contraindicated for antiplatelet therapy or anticoagulant therapy&#xD;
&#xD;
          2. Patients with significant allergic reaction to contrast medium&#xD;
&#xD;
          3. Patients who are pregnant or may be pregnant&#xD;
&#xD;
          4. Patients with left ventricle ejection fraction of &lt;30%&#xD;
&#xD;
          5. Patients deemed inappropriate by physician&#xD;
&#xD;
        Angiographic Exclusion Criteria:&#xD;
&#xD;
          1. Main branch reference vessel diameter of ≥4.5 mm by angiography&#xD;
&#xD;
          2. Bypass grafts lesions&#xD;
&#xD;
          3. In-stent restenosis lesions&#xD;
&#xD;
          4. Highly tortuous lesions of ≥60 degrees&#xD;
&#xD;
          5. Highly calcified lesions in which full stent dilatation may not be possible&#xD;
&#xD;
          6. The target lesion with remote lesions in the same vessel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenya Nasu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toyohashi Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuji Oikawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Higashi Cardiovascular Clinic</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>4400836</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vulnerable Plaque Society</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>4400850</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyohashi Heart Center</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>4418530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Chiba Medical Center</name>
      <address>
        <city>Ichihara</city>
        <state>Chiba</state>
        <zip>2990111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southen Tohoku Research Institute</name>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <zip>9638563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Cardiovascular Center</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>3710004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kihara Junkanki Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chitose City Hospital</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>0668550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0608648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinko Kagogwa Hospital</name>
      <address>
        <city>Kakogawa</city>
        <state>Hyogo</state>
        <zip>6750115</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanda City Hospital</name>
      <address>
        <city>Sanda</city>
        <state>Hyogo</state>
        <zip>6691321</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <zip>5980048</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsubara Tokushukai Hospital</name>
      <address>
        <city>Matsubara</city>
        <state>Osaka</state>
        <zip>5800032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyou</state>
        <zip>1060032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Police Hospital</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>1028161</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itabashi Chuo Medical Center</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>1740051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>1600023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2008</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kenya Nasu</name_title>
    <organization>Toyohashi Heart Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

